TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program
1. TGTX completed a $100 million share repurchase program. 2. New $100 million repurchase program authorized by the Board of Directors. 3. Share repurchase reflects management's confidence in TGTX's market value. 4. BRIUMVI's long-term growth potential is expected to increase. 5. Company continues to focus on shareholder value and product development.